Trials / Recruiting
RecruitingNCT06015048
A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.
A Phase 1b/2 Study to Evaluate the Safety, Tolerability and Efficacy of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 364 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A1811 combined with other antitumor therapies in advanced solid tumors. To explore the reasonable dosage of SHR-A1811 combined with other antitumor therapies for advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-A1811 combined with Pyrotinib. | SHR-A1811 combined with Pyrotinib |
| DRUG | SHR-A1811 combined with other antitumor therapies | SHR-A1811 combined with other antitumor therapies |
Timeline
- Start date
- 2023-08-11
- Primary completion
- 2026-11-01
- Completion
- 2026-12-29
- First posted
- 2023-08-29
- Last updated
- 2024-08-05
Locations
15 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06015048. Inclusion in this directory is not an endorsement.